ReviewTranslational andrology and urology2015
Active surveillance and focal therapy for low-intermediate risk prostate cancer.
Review in Translational andrology and urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Article
- Article
- Prostate Cancer and the Rise of Focal Laser Therapies: A Narrative Review of Benefits and Limitations.Journal of lasers in medical sciences · 2025Review
- MicroRNA in prostate cancer: from biogenesis to applicative potential.BMC urology · 2024Review
- Active surveillance in low- and intermediate-risk prostate cancer.Asian journal of andrology · 2024Article
- Chromosome-specific segment size alterations are determinants of prognosis in prostate cancer.Saudi journal of biological sciences · 2023Article
- Challenges to Recruiting Men on Active Surveillance for Prostate Cancer in Clinical Chemoprevention Trials.Cancers · 2023Article
- Effects of Green Tea Catechins on Prostate Cancer Chemoprevention: The Role of the Gut Microbiome.Cancers · 2022Review
- Clinicopathological characteristics of glomeruloid architecture in prostate cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Green tea extract for prevention of prostate cancer progression in patients on active surveillance.Oncotarget · 2018Review
- Focal therapy for localized prostate cancer: is there a "middle ground" between active surveillance and definitive treatment?Asian journal of andrology · 2018Article
- MR-guided biopsy and focal therapy: new options for prostate cancer management.Current opinion in urology · 2018Review
- [High intensity focused ultrasound (HIFU) : Importance in the treatment of prostate cancer].Der Radiologe · 2017Article
- Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer.Clinical and translational imaging · 2017Article
- An update on focal therapy for prostate cancer.Nature reviews. Urology · 2016Review
- Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.Virchows Archiv : an international journal of pathology · 2016Article
- Active surveillance for nonmuscle invasive bladder cancer.Investigative and clinical urology · 2016Review
- Contemporary Strategies for Clinical Chemoprevention of Localized Prostate Cancer.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low risk and many cases of low-intermediate risk prostate cancer, are indolent, have little or no metastatic potential, and are not life threatening. Major advances have been made in understanding who these patients are, and in encouraging the use of conservative management in such individuals. Conservative management incorporates the early identification of those 'low risk' patients who harbor higher risk disease, and benefit from definitive therapy. Based on the current algorithm of PSA followed by systematic biopsy, this represents about 30% of newly diagnosed low risk patients. A further small proportion of patients with low risk disease demonstrate biological progression to higher grade disease. Men with lower risk disease can defer treatment, usually for life. Men with higher risk disease that can be localized to a relatively small volume of the prostate may be candidates for focal, prostate sparing therapy. The results of active surveillance, embodying conservative management with selective delayed intervention for the subset who are re-classified as higher risk over time based on repeat biopsy, imaging, or biomarker results, have shown that this approach is safe in the intermediate to long term, with a 1-5% cancer specific mortality at 15 years. Further refinement of the surveillance approach is ongoing, incorporating MRI, targeted biopsies, and molecular biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.